Abstract
Childhood acute lymphoblastic and myeloid leukemias are stratified into molecular and cytogenetic subgroups important for prognosis and therapy. Studies have shown that gene expression profiles can discriminate between leukemia subtypes. Thus, proteome analysis similarly holds the potential for characterizing different subtypes of childhood leukemia. We used surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to analyze cell lysates from childhood leukemia cell lines as well as pretreatment leukemic bone marrow derived from childhood leukemia cases. Comparison of the acute myeloid leukemia (AML) cell line, Kasumi, and the biphenotypic myelomonocytic cell line, MV4;11, with the acute lymphoblastic leukemia (ALL) cell lines, 697 and REH, revealed many differentially expressed proteins. In particular, one 8.3?kDa protein has been identified as a C-terminal truncated ubiquitin. Analysis of childhood leukemia bone marrow showed differentially expressed proteins between AML and ALL, including a similar peak at 8.3?kDa, as well as several proteins that differentiate between the ALL t(12;21) and hyperdiploid subtypes. These results demonstrate the potential for proteome analysis to distinguish between various forms of childhood leukemia. Future analyses are warranted to validate these findings and to investigate the role of the C-terminal truncated ubiquitin in the etiology of ALL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Parkin DM, Stiller CA, Draper GJ, Bieber CA . The international incidence of childhood cancer. Int J Cancer 1988; 42: 511–520.
Incidence of and mortality from acute lymphocytic leukemia, 1980–1999. J Natl Cancer Inst 2003; 95: 578.
Greaves M . Childhood leukaemia. BMJ 2002; 324: 283–287.
Bhatia S, Robison LL . Epidemiology of leukemia and lymphoma. Curr Opin Hematol 1999; 6: 201–204.
Greaves MF, Wiemels J . Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003; 3: 639–649.
Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 2951–2959.
Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617–1628.
Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, Kern W et al. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia 2004; 18: 63–71.
Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133–143.
Cui JW, Wang J, He K, Jin BF, Wang HX, Li W et al. Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 2004; 10: 6887–6896.
Cui JW, Wang J, He K, Jin BF, Wang HX, Li W et al. Two-dimensional electrophoresis protein profiling as an analytical tool for human acute leukemia classification. Electrophoresis 2005; 26: 268–279.
Ota J, Yamashita Y, Okawa K, Kisanuki H, Fujiwara S, Ishikawa M et al. Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene 2003; 22: 5720–5728.
Issaq HJ, Veenstra TD, Conrads TP, Felschow D . The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587–592.
Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 2003; 19: 229–238.
Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP . Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 2003; 237: 660–664; discussion 664–665.
Fung E, Diamond D, Simonsesn AH, Weinberger SR . The use of SELDI ProteinChip array technology in renal disease research. Methods Mol Med 2003; 86: 295–312.
Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res 2004; 3: 1261–1266.
Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005; 11: 1073–1085.
Gretzer MB, Chan DW, van Rootselaar CL, Rosenzweig JM, Dalrymple S, Mangold LA et al. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF. Prostate 2004; 60: 325–331.
Ma X, Buffler PA, Gunier RB, Dahl G, Smith MT, Reinier K et al. Critical windows of exposure to household pesticides and risk of childhood leukemia. Environ Health Perspect 2002; 110: 955–960.
Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990; 87: 7071–7075.
Shimbara N, Orino E, Sone S, Ogura T, Takashina M, Shono M et al. Regulation of gene expression of proteasomes (multi-protease complexes) during growth and differentiation of human hematopoietic cells. J Biol Chem 1992; 267: 18100–18109.
Finley D, Chau V . Ubiquitination. Annu Rev Cell Biol 1991; 7: 25–69.
Pickart CM . Ubiquitin enters the new millennium. Mol Cell 2001; 8: 499–504.
Ichihara A, Tanaka K . Roles of proteasomes in cell growth. Mol Biol Rep 1995; 21: 49–52.
Rocken C, Ebert MP, Roessner A . Proteomics in pathology, research and practice. Pathol Res Pract 2004; 200: 69–82.
Diamandis EP . Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003; 49: 1272–1275.
Acknowledgements
This work was supported by NIH Grants P42ES04705 and P30 ES01896 (to MTS) and R01 ES09137 (to PAB) and the National Foundation for Cancer Research. We thank Ji-Young Woo for her help with processing of the childhood leukemia bone marrow samples and Dr Nina Holland for help in establishing the database employed in these studies.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu).
Supplementary information
Rights and permissions
About this article
Cite this article
Hegedus, C., Gunn, L., Skibola, C. et al. Proteomic analysis of childhood leukemia. Leukemia 19, 1713–1718 (2005). https://doi.org/10.1038/sj.leu.2403897
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403897
Keywords
This article is cited by
-
Adamantinomatous craniopharyngioma: advances in proteomic research
Child's Nervous System (2021)
-
The consumption of seaweed as a protective factor in the etiology of breast cancer: proof of principle
Journal of Applied Phycology (2013)
-
Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia
Proteome Science (2009)
-
Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer
Oncogene (2007)
-
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia
Molecular Biotechnology (2007)